USA - NASDAQ:HCM - US44842L1035 - ADR
ChartMill assigns a Buy % Consensus number of 84% to HCM. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-22 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2024-08-01 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-11-24 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2023-11-10 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-24 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2022-08-09 | Goldman Sachs | Maintains | Neutral |
| 2022-08-02 | Goldman Sachs | Maintains | Neutral |
| 2021-09-22 | Goldman Sachs | Downgrade | Buy -> Neutral |
27 analysts have analysed HCM and the average price target is 16.25 USD. This implies a price increase of 7.74% is expected in the next year compared to the current price of 15.085.
The consensus rating for HUTCHMED CHINA-ADR (HCM) is 83.7037 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering HUTCHMED CHINA-ADR (HCM) is 27.